Meeting
2013 ASCO Annual Meeting
A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL).
Authors
Herbert Aaron Eradat
David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA
Herbert Aaron Eradat , Steven E. Coutre , Jacqueline Claudia Barrientos , Kanti Roop Rai , Charles Michael Farber , Peter Hillmen , Jeff Porter Sharman , Paolo Ghia , Bertrand Coiffier , Jan Andrzej Walewski , Zwi N. Berneman , Susan Mary O'Brien , Jennifer R. Brown , Sissy Peterman , Roger D. Dansey , Thomas Michael Jahn , Paula Cramer , Michael J. Hallek
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Leukemia
Clinical Trial Registration Number
NCT01569295
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS7133)
DOI
10.1200/jco.2013.31.15_suppl.tps7133
Abstract #
TPS7133
Poster Bd #
46E
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL).
First Author: Herbert Aaron Eradat
Poster
2014 ASCO Annual Meeting
A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib in combination with bendamustine and rituximab for previously untreated chronic lymphocytic leukemia.
First Author: Gilles A. Salles
Poster
2013 ASCO Annual Meeting
A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL).
First Author: Sven De Vos
Poster
2013 ASCO Annual Meeting
A phase III, randomized, controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL).
First Author: Ian Flinn